Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) - Bonaca, Marc P.; Nault, Patrice; Giugliano, Robert P.; Keech, Anthony C.; Pineda, Armando Lira; Kanevsky, Estella; Kuder, Julia; Murphy, Sabina A.; Jukema, J. Wouter; Lewis, Basil S.; Tokgozoglu, Lale; Somaratne, Ransi; et al. (Circulation (New York, N.Y.), 2018)
Keywords: Aged; Amputation; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents - adverse effects; Anticholesteremic Agents - therapeutic use; Biomarkers - blood; Cholesterol, LDL - blood; Down-Regulation; Dyslipidemias - blood; Dyslipidemias - diagnosis; Dyslipidemias - drug therapy; Dyslipidemias - mortality; Female; Humans; Limb Salvage; Male; Middle Aged; Peripheral Arterial Disease - blood; Peripheral Arterial Disease - diagnosis; Peripheral Arterial Disease - mortality; Peripheral Arterial Disease - therapy; Proprotein Convertase 9 - antagonists & inhibitors; Proprotein Convertase 9 - metabolism; Risk Factors; Serine Proteinase Inhibitors - adverse effects; Serine Proteinase Inhibitors - therapeutic use; Time Factors; Treatment Outcome; atherosclerosis; amputation; cholesterol, LDL; evolocumab; peripheral arterial disease; PCSK9 protein, human; intermittent claudication